Acurx Pharmaceuticals (ACXP) Stock Price, News & Analysis

Company Overview

Acurx Pharmaceuticals, Inc., headquartered in King of Prussia, Pennsylvania, is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel anti‐infective therapies. The company’s research platform leverages insights into bacterial virulence regulation and quorum sensing pathways to design small-molecule candidates aimed at reducing pathogen toxicity and biofilm formation. By targeting key mechanisms of infection rather than bacterial viability alone, Acurx seeks to offer differentiated treatment options that may help address the growing challenge of antibiotic resistance.

Acurx’s lead product candidates are being developed to treat acute bacterial skin and skin structure infections (ABSSSI), including cases caused by drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA). These candidates are engineered to limit bacterial communication and toxin production, potentially enhancing host response while preserving the normal microbiome. The company advances its programs through preclinical studies with the intent to move into first-in-human trials once regulatory filings are secured.

Since its founding in the mid-2010s, Acurx has established collaborations with academic laboratories and industry partners to bolster its drug discovery efforts and accelerate preclinical development. While its operations are predominantly U.S.-based, the company aspires to serve international markets following regulatory approvals. Acurx’s management team comprises professionals with experience in infectious disease research, pharmaceutical development, and regulatory strategy, reflecting a collective commitment to addressing unmet needs in anti‐infective therapy.

Key Stats

• Today's Range: $1.94 to $2.13
• 50-Day Range: $1.35 to $6.63
• 52-Week Range: $1.33 to $21.00
• Volume: 201,574 shs
• Average Volume: 2.30 million shs
• Market Capitalization: $5.72 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $31.00
• Consensus Rating: Hold

Acurx Pharmaceuticals Stock Analysis - MarketRank™

Acurx Pharmaceuticals scored higher than 50% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Acurx Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Acurx Pharmaceuticals has a consensus price target of $31.00, representing about 1,450.0% upside from its current price of $2.00.

Amount of Analyst Coverage

Acurx Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Acurx Pharmaceuticals are expected to grow in the coming year, from ($2.68) to ($1.85) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Acurx Pharmaceuticals is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Acurx Pharmaceuticals is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Acurx Pharmaceuticals has a P/B Ratio of 0.97. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.17% of the float of Acurx Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Acurx Pharmaceuticals has a short interest ratio ("days to cover") of 0.62, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Acurx Pharmaceuticals has recently decreased by 7.35%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Acurx Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Acurx Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Acurx Pharmaceuticals this week, compared to 2 articles on an average week.

Search Interest

Only 9 people have searched for ACXP on MarketBeat in the last 30 days. This is a decrease of -61% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Acurx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -86% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Acurx Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

20.30% of the stock of Acurx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

11.53% of the stock of Acurx Pharmaceuticals is held by institutions.

ACXP Stock Analysis - Frequently Asked Questions

How have ACXP shares performed this year?

Acurx Pharmaceuticals' stock was trading at $2.49 at the start of the year. Since then, ACXP stock has decreased by 19.7% and is now trading at $2.00.

How were Acurx Pharmaceuticals' earnings last quarter?

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) posted its quarterly earnings results on Thursday, March, 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.01) by $0.70.
Read the conference call transcript.

When did Acurx Pharmaceuticals' stock split?

Shares of Acurx Pharmaceuticals reverse split on the morning of Tuesday, August 5th 2025.A 1-20 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 4th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Acurx Pharmaceuticals IPO?

Acurx Pharmaceuticals (ACXP) raised $15 million in an IPO on Friday, June 25th 2021. The company issued 2,500,000 shares at a price of $5.00-$7.00 per share. Alexander Capital, L.P. and Network 1 Financial Securities served as the underwriters for the IPO.

Who are Acurx Pharmaceuticals' major shareholders?

Top institutional shareholders of Acurx Pharmaceuticals include Prospect Financial Services LLC (0.48%). Insiders that own company stock include David P Luci and Joseph C Scodari.
View institutional ownership trends.

How do I buy shares of Acurx Pharmaceuticals?

Shares of ACXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Acurx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Acurx Pharmaceuticals investors own include Avino Silver & Gold Mines (ASM), PayPal (PYPL), Adverum Biotechnologies (ADVM), Rolls-Royce Holdings PLC (RYCEY), AbCellera Biologics (ABCL) and Atai Beckley (ATAI).

Company Calendar

• Last Earnings: 3/12/2026
• Today: 5/05/2026
• Next Earnings (Estimated): 5/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ACXP
• CIK: 1736243
• Web: www.acurxpharma.com
• Phone: 917-533-1469
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Acurx Pharmaceuticals: $31.00
• High Price Target: $31.00
• Low Price Target: $31.00
• Potential Upside/Downside: +1,450.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.63)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.97 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -215.54%
• Return on Assets: -128.70%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.18
• Quick Ratio: 3.18

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.07 per share
• Price / Book: 0.97

Miscellaneous

• Outstanding Shares: 2,860,000
• Free Float: 2,275,000
• Market Cap: $5.72 million
• Optionable: No Data
• Beta: -2.09